LYCOS RETRIEVER 
Cell
built 643 days ago
Cell Therapeutics (CTI) is a toxic avenger. The firm creates more effective and less toxic treatments for various forms of cancer. Lead drug candidate Xyotax is based on Taxol, the successful cancer fighter from Bristol-Myers Squibb. It uses a water soluble, biodegradable protein to deliver the drug, allowing cancer-fighting agents to home in on tumors, as well as reducing toxic side effects. The company is exploring its use to treat non-small cell lung and ovarian cancer. Other drugs in the CTI pipeline include Pixantrone, which targets non-Hodgkin's lymphoma, and CT-2106, which the company is developing as an ovarian and colorectal cancer treatment.
Source:
Cell Biology is a multidisciplinary Ph.D Graduate program at The University of Texas Medical Branch., Galveston, Texas. This Program is part of the Graduate School of Biomedical Sciences. The academic program provides training in a variety of disciplines using experimental approaches in Cell and Molecular Biology.
Source:
SEATTLE, Jan. 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX: CTIC) announced today that it priced an offering of 800,000 shares of CTI new common shares. This share issue will equate to approximately 1.2% percent of CTI's market capitalization. The offering is expected to close on Wednesday, January 16, and to raise approximately $1,270,000 (euros 856.000). The shares will be sold to Societe Generale, pursuant to the Step-Up Equity Financing Agreement entered into by CTI and Societe Generale, dated June 21, 2006 as amended. CTI intends to use the net proceeds for general corporate purposes, including the preparation and filing of new drug applications and preclinical and clinical trials.
Source:
"We are pleased to welcome Chrysler as the California Fuel Cell Partnership's ninth automotive member," said Catherine Dunwoody, CaFCP's executive director. "We're looking forward to the new perspectives and ideas Chrysler will bring to the table as we all work together to commercialize this important transportation solution."
Source:
Cell Genesys is focused on the development and commercialization of cancer vaccines and gene therapies to treat major, life-threatening diseases. The company is conducting clinical trials of GVAX(R) cancer vaccines in prostate cancer, pancreatic cancer, lung cancer and myeloma and expects to initiate new studies in acute leukemia during 2001. Preclinical stage programs include gene therapies for cancer, hemophilia and cardiovascular disorders. Cell Genesys' majority-owned subsidiary, Ceregene, is focused on gene therapies for central nervous system disorders. Cell Genesys ... continues to hold a 10.5 percent equity interest in its former subsidiary, Abgenix, an antibody product company. For additional information, please visit the company's web site at http://www.cellgenesys.com.
Source:
Technical details for the Cell have not yet been released, but informed speculation indicates that one cell chip will do 1 trillion floating point operations per second, 1 TFLOP. This speed is several hundred times faster than a high-end personal computer.
Source:
MORE ABOUT
Cell